FDA Grants Priority Review For Promacta / Revolade (Eltrombopag)

GlaxoSmithKline announced that the United States Food and Drug Administration (FDA) has granted Priority Review for Promacta® / Revolade® (eltrombopag) for the short-term treatment of patients with chronic idiopathic thrombocytopenic purpura (ITP). Eltrombopag is an investigational, once-daily oral treatment that induces the production of cells in the bone marrow to generate platelets, which are critical in minimising the incidence of bleeding in chronic ITP.

More: continued here

Filed under: Blood on March 14th, 2008